| 產品編號 | bs-1682R |
| 英文名稱 | CIB1 Rabbit pAb |
| 中文名稱 | 鈣整合素結合蛋白1抗體 |
| 別 名 | Sip2-28; Cibkip; Kip; Prkdcip; CIB1_HUMAN; Calcium and integrin-binding protein 1; CIB; Calcium-and integrin-binding protein; CIBP; Calmyrin; DNA-PKcs-interacting protein; Kinase-interacting protein; KIP; SNK-interacting protein 2-28; SIP2-28. |
| 研究領域 | 腫瘤 轉運蛋白 細胞粘附分子 結合蛋白 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | (predicted: Human,Mouse,Rat,Rabbit,Pig,Cow,Dog,GuineaPig,Horse) |
| 產品應用 | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 22 kDa |
| 檢測分子量 | |
| 細胞定位 | 細胞核 細胞漿 細胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CIB1: 101-191/191 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產品介紹 |
CIB1(Calcium and integrin binding 1) may convert the inactive conformation of integrin alpha-IIb/beta3 to an active form through the binding to the integrin cytoplasmic domain. Function: May convert the inactive conformation of integrin alpha-IIb/beta3 to an active form through binding to the integrin cytoplasmic domain. Induces cell migration and spreading mediated through integrin (possibly via focal adhesion complexes). Functions as a negative regulator of stress activated MAP kinase (MAPK) signaling pathways. May play a role in regulation of apoptosis. Interacts with and up-regulates PTK2 activity. Down regulates inositol 1,4,5-trisphosphate receptor-dependent calcium signaling. Subunit: Monomer. Interacts with the heterodimeric integrin alpha-IIb/beta3. Interacts with the protein kinases PLK2/SNK and with the region immediately upstream of the kinase domain of DNA-PK. Interacts with PLK3; leading to inhibit PLK3 kinase activity. Interacts with PSEN2. Interacts with MYO1C (By similarity). Interacts (via C-terminus) with F8. Interacts with NBR1 (via C-terminus). Interacts with FEZ1 (via C-terminus). Interacts with UBR5 (via C-terminus); the interaction is sensitive to DNA damage, and may target CIB1 for ubiquitin-mediated degradation. Interacts with IFI6. Interacts with BCL2. Interacts with TAS1R2 (via C-terminus); this interaction is independent of the myristoylation state of CIB1. Interacts with ITPR3; in a calcium dependent manner. Interacts with PTK2/FAK1. Interacts with MAP3K5; inhibiting MAP3K5 activation by phosphorylation, and its subsequent interaction with TRAF2. Subcellular Location: Membrane. Cytoplasm. Nucleus. Cell projection, filopodium. Apical cell membrane. Localizes to the perinuclear region in the presence of NBR1. Colocalizes with TAS1R2 in apical regions of taste receptor cells. Tissue Specificity: Ubiquitous. Similarity: Contains 2 EF-hand domains. SWISS: Q99828 Gene ID: 10519 Database links: Entrez Gene: 10519 Human Omim: 602293 Human SwissProt: Q99828 Human Unigene: 715556 Human CIB1是通過抑制eurekalert AK1（p21蛋白激酶）來發揮作用的。當CIB1激活PAK1后，會促發一系列蛋白磷酸化，從而抑制細胞遷移。CIB1在抑制腫瘤轉移中有很重要的作用。 |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
